GTBP 面临历史反向拆股带来的风险，以及为临床试验融资所需的未来增发/摊薄预期。

Can we take a look at GT Biioarma today? It's been on a nice uptrend. Yeah, we can absolutely take a look at that. I did see that it basically traded up to its 200 day. So, um we'll see what uh GTBP does here today.

I did put it in another window. If I forget when we get to the stock section, remind me. We'll get to that.

Can we take a look at this GTBP for uh for Robert maybe? Robert, I think that you I can't remember exactly what you said earlier, but you said this was looking interesting or has been on a run recently.

Uh, indeed it has. And actually, just looking at this, I I mean, great action here, right? I don't know if this was a split or a pop. I'll I'll look there on the chart, but basically this little pull back down into a big bigger move here.

Um, this was a split because I have it split adjusted in my broker. Let me just confirm that here real quick. Um, yeah, this did a reverse 2 days ago. Uh, excuse me, 7 days ago.

So, the last reverse split here was 1 for 25. That was on September 8th. It's worth noting that the previous reverse split that it did was 2024 in February where it did a 1 for30.

And in fact, the stock has only done reverse splits. So, I would say careful with this one just because of the history, although they're not doing them once a month like some of these other junkers that we've seen here.

Looking into the fun. Here's the what the intraday chart looks like. It is. Oh, it's down 5%. It actually looked like it was going to make a a little bit of a rip there. Gave that back up. Now is actually sitting down 3% here.

Looking in uh looking into this, it has two clinical stage triacific killer engager candidates in its pipeline right now. This is the whole thing on what this is moving on. Uh GTB 3650.

I'm gonna have a imp I'm not going to be able to remember these so I'm glad I'm able to read this from a stat sheet here. GTB 3650 um targets are some refractory expresses blood cancer refractory AML and high-risisk MDS.

It's a phase one dose escalation trial. Cohort 4 is complete and cohort 5 enrollment is underway with the data update expected in the second half of 2026. So, it actually looks like we're expecting data here on GTB 3650.

They also have GTB 5550, which is a phase 1 basket trial across several solid tumors, prostate, ovarian, breast, head and neck, lung, pancreatic, and bladder. It's notable as the first nanobbody trike dosed subcutaneously rather than IV.

The first patient was dosed in May of 2026 and there is an update expected in the second half of this year.

So, so real quick, if you just go to their website and click on their um their product pipeline, you have a a nice graphical representation of all their trike uh clinical pipelines uh that are uh undergoing uh pre-clinical or clinical trials and everything that you were just saying is all in those is annotated there uh in that.

So there you go. Perfect. So there you go. That's if if you're looking for the information and and what they've got going on, this is this is the place to go. Their their actual website.

Okay. Well, for me, this is uh more more about and I'd have to go through their u their second quarter financial results uh that came out in August 14th and see what kind of um you know if they got any uh uh plans for raising capital because I'm looking at their balance sheet.

Uh they've got a little less than five million in the bank and on a quarterly basis they're they're burning uh you know over the last three quarters they're burning about that uh give or take you know a million or two.

So, I think that they're going to need to do uh some financial work here and uh I don't know if you know there's something that they already mentioned in their earnings report, then that's what I was talking about going and having a look.

But uh if there isn't, then I don't see anything that they've got planned. Just looking uh at uh my uh my screen here. So, there could be some kind of capital race coming uh or some shared illusion event uh because they're going to need this.

And you know, we just talked about how they're not very far into these clinical trials and they're only going to get more expensive as these clinical trials go on. Phase two is going to require a larger pool of people.

Phase three even larger than that. So, I I get the sense that there's going to have to be some kind of um you know, capital uh raise here unless um you know, they they get a grant uh or they uh they have a private placement, there's likely going to be some share uh dilution.

And I think that's one of the reasons why you're seeing the uh uh I think that was said there was a reverse split recently. Yeah, that's why you're seeing that reverse split. So I think this could just be uh setting up to potentially uh raise capital.

So I think that's something you just got to keep in mind when it comes to these biotech names that are going through early clinical trials and need capital.

Looks like G uh TBP is open and uh out of that halt and it dropped down to the uh the sideways price action from the pre-market of yesterday and is getting support there. Actually, look at that.

That that extends from the after hours into the pre-market yesterday >> and that is where the price has gone down to and looking for some support. Whether or not it holds here, can't say, but that's where it's uh currently trying to bounce.